Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$380.2M
104M shares
52-week range
$2.72 – $6.42
13% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $261.0K | $78.0K | $155.0K | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$261.0K | −$78.0K | −$155.0K | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $49.5M | $20.8M | $31.3M | $38.4M | $24.3M | $27.7M | $73.3M | $154.2M |
| Operating income | −$62.7M | −$23.2M | −$42.8M | −$50.5M | −$36.5M | −$41.8M | −$90.9M | −$172.5M |
| EBITDA | −$60.8M | −$23.1M | −$42.6M | −$50.3M | −$35.0M | −$36.6M | −$80.3M | −$165.3M |
| Net income | −$61.4M | −$23.1M | −$42.3M | −$50.6M | −$35.4M | −$36.9M | −$80.6M | −$165.7M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -22.85 | -2.51 | -3.56 | -2.93 | -1.33 | -0.84 | -1.32 | -2.27 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-1.66 | $-1.82–$-1.42 | 6 |
| 2027 | $58M | $-1.26 | $-1.77–$-0.85 | 5 |
| 2028 | $152M | $-0.57 | $-1.64–$1.73 | 5 |
| 2029 | $331M | $0.42 | $-0.01–$1.35 | 1 |
Forward consensus · source: Financial Modeling Prep
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
www.larimartx.comNo one on the platform currently holds LRMR.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 739,942 | $3.3M |
No one on the platform has traded LRMR yet.
| $666M |
| — |
| ANROAlto Neuroscience, Inc. | $28.07 | +3.81% | $985M | — |
| DBVTDBV Technologies S.A. | $16.00 | -0.06% | $383M | — |
Source: Financial Modeling Prep · peers by sector/industry
$LRMR it's 1/43 equal to 2% had a nap if we removed 9 of them who had treatment holidays of 2.5 years before restarting the treatment. My opinion with DD
View on StockTwits ↗$LRMR 25% of the patients had anaphylaxis , is it safe enough to be approved ? anaphylaxis can be fatal.
View on StockTwits ↗$LRMR this is a tough one, curious to see why those 10 patients with previous treatment stopped and then restarted. Clearly going to get a black box warning, but who cares for FA. Biomarker data is great and patients seem to do better but that’s compared to historical. If they can capture even a third of the TAM in the USA I could see this thing 3-5x. Need to find some patient stories.
View on StockTwits ↗$LRMR if insiders buy here it could move the stock up but not above 3.8$ Don't see analysts raising or reducing the price target much now. It could be a long wait, and with their cash burn rate which is almost $50 Million it could get frustrating.
View on StockTwits ↗$LRMR Sigh... this is incredibly frustrating. Thinking strictly as an investor, it’s deeply annoying. Yet, it’s hard to flat-out criticize LRMR when they are genuinely putting patients first. To be honest, I took it for granted that the anaphylaxis data would come back well-managed. But the reality? The numbers spiked significantly because they included patients who had previously received the drug. Breaking down the data, it looks like this: 1. Based on the September 2025 announcement, the data (mFARS, 9-HPT) from the group treated for over a year confirms that the drug’s efficacy is being sustained as of the March 2026 cutoff. 2. As evidenced by the changes in FACOMS scores, it is clear that the company is enrolling moderate-to-severe patients. 3. While we can see the general direction, the overall data has become highly complicated. 4. They have cleared one regulatory hurdle, and LRMR remains undervalued considering its cash position and the potential for a PRV
View on StockTwits ↗$LRMR Reata was sold to $BIIB for $7.3B even though Skyclarys was aimed at helping patients deal with the inflammation and oxidative stress from the disease progression whereas Larimar's drug essentially replaces the protein in the body that causes the disease in the first place... I have to believe that LRMR is worth a tad more than $300M a year out from first sales, lol.
View on StockTwits ↗$LRMR It is just speculation aimed at buying at a low price; in practice, the FDA has requested the data tables for accelerated approval. It represents a market for the drug worth over $2 billion a year.
View on StockTwits ↗$LRMR Reaction to the news is kind of fascinating, LRMR basically proved that the drug genuinely works, actually addresses the underlying issue with the disease and the only real issue was with anaphylaxis in some patients... and it looks like that primarily occurs in patients that were on drug then stopped then started again; - easy solution would be to stay on drug. Thanks to Accelerated Approval, drug will likely be selling in the US in about a year...
View on StockTwits ↗$LRMR so how long we got now till we see over $4 again?
View on StockTwits ↗$LRMR Safety is managable. Increased & sustained skin FXN level satisfies FDA-agreed sarrogate endpoint for an accelerated approval. The label, if approved, will be broad, e.g. including kids (age 2 and up) and FA patients of all stages (pre-symptom, early, advanced), 1st disease-modifying treatment, 1st line & long-term continurous usage, per CEO. NFA
View on StockTwits ↗$LRMR anyone else showing current price of $0.00 on Etrade?
View on StockTwits ↗$LRMR morgan Stanley and citizens were on the call in addition to some other medium funds.. get in when the bears are giving out free money before the tutes put their orders in. Not financial advice.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.